OCUMENSION-B (01477): Fluocinolone acetonide intravitreal implant approved by the National Medical Products Administration for production in mainland China

OCUMENSION-B (01477) announced that the group's fluocinolone acetonide intravitreal implant has recently been approved by the National Medical Products Administration of the People's Republic of China for production in mainland China. The product's registration application was submitted via the Class 4 chemical drug pathway and was included in the National Medical Products Administration's priority review and approval procedure for drug marketing authorization; its production technology was acquired by the group through technology transfer, and process transfer and process validation have been completed.